Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy

British Journal of Cancer

Volumn 104, Issue 4, 2011, Pages 599-604

  Osterlund P ^a   Soveri, L M ^a   Isoniemi, H ^a   Poussa, T ^b   Alanko, T ^a   Bono, P ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NOKIA RESEARCH CENTER   (United States)

Author keywords

bevacizumab; hypertension; predictive factor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM ANTAGONIST; CAPECITABINE; CETUXIMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIASTOLIC BLOOD PRESSURE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79951673901     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.2     Document Type: Article

References (13)

1. Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, Joensuu H (2009) Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 20(2): 393-394
2. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28(6): 949-954
3. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20(21): 4368-4380 (Pubitemid 35266299)
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342 (Pubitemid 38702844)
5. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H (2005) Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97(13): 981-989 (Pubitemid 41430564)
6. Jubb AM, Oates AJ, Holden S, Koeppen H (2006) Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6(8): 626-635 (Pubitemid 44140860)
7. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler WM, Elliott WJ, Ratain MJ (2009) Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 15(19): 6250-6257
8. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23(5): 460-468
9. Rini BI, Cohen DP, Lu D, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ (2010a) Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Proc Am Soc Clin Oncol Genitourinary Cancer Symposium; (Abstract 312)
10. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Ivy P, Chen HX, Dowlati A, Dreicer R (2010b) Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 28(17): e284-e285; author reply e286-e287
11. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst99(16): 1232-1239 (Pubitemid 47299901)
12. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20(2): 227-230
13. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28): 4672-4678